Warning: session_start(): open(/var/lib/php/session/sess_9doia840sg45i48gtrk2fcfv92, O_RDWR) failed: Permission denied (13) in /var/www/html/realclearpolitics.com/httpdocs/congressional_bill_tracker/app/application/mvc.php on line 3 Warning: file_get_contents(http://congress.api.sunlightfoundation.com/bills?apikey=f323a285321542e3925601990ef5c589&congress=114&bill_type=hr&number=639&fields=versions,latest_version): failed to open stream: HTTP request failed! HTTP/1.1 504 Gateway Time-out in /var/www/html/realclearpolitics.com/httpdocs/congressional_bill_tracker/app/application/model.php on line 738 RCP Congressional Bill Tracker - H.R. 639

CONGRESSIONAL BILL TRACKER

Track Members of Congress & Get Email Updates on Their Activity

H.R. 639: Improving Regulatory Transparency for New Medical Therapies Act

Title: Improving Regulatory Transparency for New Medical Therapies Act

Introduced: Feb 2, 2015 (114th Congress)

Sponsor: Rep. Joseph R. Pitts [R-PA16]

Status: Passed Senate with Changes - Message on Senate action sent to the House.

Summary: Improving Regulatory Transparency for New Medical Therapies Act (Sec. 2) This bill amends the Federal Food, Drug, and Cosmetic Act and the Public Health Service Act to delay the effective date of approval of a drug, biological product, or animal drug for which the Food and Drug Administration (FDA) recommends controls under the Controlled Substances Act until the Department of Justice (DOJ) issues a final interim rule for the drug. This delay also applies to conditional approval and indexing of animal drugs. This bill amends the Controlled Substances Act to require the DOJ to issue a final interim rule for a drug product recommended for controls by the FDA not later than 90 days after DOJ receives a recommendation for controls or the FDA approves the drug. The final interim rule is effective immediately. For purposes of submitting an application to extend a patent, a drug product recommended for controls is considered to be approved and have permission for commercial marketing and use on the date of FDA approval or the date an interim final rule is issued, whichever is later. (Sec. 3) Timelines are established for DOJ to either register an applicant to manufacture a controlled substance for a clinical trial or serve an order to show cause upon the applicant.

Votes

Warning: Unknown: open(/var/lib/php/session/sess_9doia840sg45i48gtrk2fcfv92, O_RDWR) failed: Permission denied (13) in Unknown on line 0 Warning: Unknown: Failed to write session data (files). Please verify that the current setting of session.save_path is correct (/var/lib/php/session) in Unknown on line 0